Stock IMMX IMMIX BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Delayed Nasdaq
Other stock markets
 11:41:45 2024-06-10 am EDT 		5-day change 1st Jan Change
2.03 USD 0.00% Intraday chart for Immix Biopharma, Inc. +4.10% -70.66%
May. 10 Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation CI
May. 09 Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
CI
Immix Biopharma Unit Says NXC-201 Shows 100% Overall Response Rate in Light Chain Amyloidosis Study
MT
Roth MKM Initiates Immix Biopharma to Buy Rating With $14 Price Target
MT
Immix Unit Says AL Amyloidosis Drug Candidate Showed 100% Complete Response Rate in Clinical Study
MT
Immix Biopharma Says Cancer Drug IMX-110 Showed Higher Survival Rate Versus Johnson & Johnson Unit's Trabectedin in Mice Study
MT
Immix Biopharma Says IMX-110 Candidate Elicits 50% Response Rate in Soft Tissue Sarcoma Study in Mice
MT
Immix Biopharma, Inc IMX-110 Produces 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMMX Stock
  4. News Immix Biopharma, Inc.
  5. Analyst Reco.